| Literature DB >> 31029943 |
Catarina Oliveira1, Donatella Bagetta2, Fernando Cagide1, José Teixeira3, Ricardo Amorim3, Tiago Silva3, Jorge Garrido4, Fernando Remião5, Eugenio Uriarte6, Paulo J Oliveira7, Stefano Alcaro2, Francesco Ortuso8, Fernanda Borges9.
Abstract
The discovery of new chemical entities endowed with potent and selective acetylcholinesterase (AChE) and/or butyrylcholinesterase (BChE) inhibitory activity is still a relevant subject for Alzheimer's disease therapy. Therefore, a small library of benzoic based amide nitrones (compounds 24 to 42) was synthesized and screened toward cholinesterase enzymes. SAR studies showed that the tert-butyl moiety is the most favourable nitrone pattern. In general, tert-butyl derivatives effectively inhibited AChE, being compound 33 the most potent (IC50 = 8.3 ± 0.3 μM; Ki 5.2 μM). The data pointed to a non-competitive inhibition mechanism of action, which was also observed for the standard donepezil. None of compounds showed BChE inhibitory activity. Molecular modelling studies provided insights into the enzyme-inhibitor interactions and rationalised the experimental data, confirming that the binding mode of nitrones 33 and 38 towards AChE has the most favourable binding free energy. The tert-butylnitrones 33 and 38 were not cytotoxic on different cell lines (SH-SY5Y and HepG2). Moreover, compound 33 was able to prevent t-BHP-induced oxidative stress in SH-SY5Y differentiated cells. Due to its AChE selectivity and promising cytoprotective properties, as well as its appropriate drug-like profile pointing toward blood-brain barrier permeability, compound 33 is proposed as a valid lead for a further optimization step.Entities:
Keywords: Acetylcholinesterase; Alzheimer's disease; Benzoic acid; Cholinesterase inhibitors; Nitrones; Oxidative stress; Spin traps
Mesh:
Substances:
Year: 2019 PMID: 31029943 DOI: 10.1016/j.ejmech.2019.04.026
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514